Vanguard Group
ALLR

Vanguard Group’s Allarity Therapeutics ALLR Stock Holding History

Vanguard Group’s Portfolio ALLR Stock Details ALLR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$266K Hold
246,708
– – ﹤0.01% 4059
2025
Q3 		$390K Buy
+246,708
New +$310K ﹤0.01% 4006

Other funds holding ALLR

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $4.11B AUM 21.98% 1-Year Est. Return
CAI
Capital Advisors Inc Tulsa, Oklahoma $6.8B AUM 26.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Group's ALLR Position: Q4 2025 in Review

Vanguard Group held its Allarity Therapeutics (ALLR) position steady in Q4 2025 at 246,708 shares worth $266K. The position accounts for ﹤0.01% of the portfolio, ranked #4059.

Vanguard Group first reported a position in ALLR in Q3 2025 and has held it in 2 quarters since. The position peaked at $390K in Q3 2025. 16 funds tracked by Wall St. Rank hold ALLR as of Q4 2025.

  • Vanguard Group held 246,708 shares of Allarity Therapeutics worth $266K as of Q4 2025.
  • Vanguard Group left its Allarity Therapeutics share count unchanged in Q4 2025.
  • Allarity Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4059 holding.
  • Vanguard Group first reported a position in Allarity Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Vanguard Group's Allarity Therapeutics position peaked at $390K in Q3 2025.
  • 16 funds tracked by Wall St. Rank held Allarity Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.